Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 18/20 | 0.64 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2539648 | 1.00 | KCNH2 (0.64) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL2536597 | 1.00 | KCNH2 (0.64) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL2536593 | 1.00 | KCNH2 (0.64) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL2543028 | 1.00 | KCNH2 (0.64) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL2539645 | 1.00 | KCNH2 (0.64) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL3373019 | 0.92 | KCNH2 (0.59) | KCNH2 | |
| SCHEMBL2328537 | 0.90 | KCNH2 (0.78) | KCNH2 | |
| SCHEMBL2328526 | 0.90 | KCNH2 (0.78) | KCNH2 | |
| SCHEMBL2325103 | 0.90 | KCNH2 (0.78) | KCNH2 | |
| SCHEMBL3666612 | 0.90 | KCNH2 (0.78) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094267-B1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-04-22 | — | — | EP | claimed |
| US-8044044-B2 | 4-(1-amino-ethyl)-cyclohexylamine derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-25 | — | — | US | claimed |
| US-20100029623-A1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-04 | — | — | US | claimed |
| EP-2094267-B1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-04-22 | — | — | EP | disclosed |
| US-8044044-B2 | 4-(1-amino-ethyl)-cyclohexylamine derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-25 | — | — | US | disclosed |
| US-20100029623-A1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029623-A1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | AHR, KRAS, CNKSR1 | KCNH2 296/4885KCNQ1 1093/4885CACNA1C 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.